Epoprostenol inhalation - Aerogen

Drug Profile

Epoprostenol inhalation - Aerogen

Alternative Names: VentaProst

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Aerogen
  • Class 2 ring heterocyclic compounds; Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pulmonary hypertension

Most Recent Events

  • 12 May 2017 Chemical structure information added
  • 18 Apr 2017 Aerogen plans a phase IIa trial for Pulmonary hypertension (Inhalation) (NCT03122730)
  • 11 Apr 2017 Preclinical trials in Pulmonary hypertension in USA (Inhalation) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top